Empirical Analysis of Drug Targets for Nervous System Disorders.
Ontology highlight
ABSTRACT: The discovery and development of drugs to treat diseases of the nervous system remains challenging. There is a higher attrition rate in the clinical stage for nervous system experimental drugs compared to other disease areas. In the preclinical stage, additional challenges arise from the considerable effort required to find molecules that penetrate the blood-brain barrier (BBB) coupled with the poor predictive value of many preclinical models of nervous system diseases. In the era of target-based drug discovery, the critical first step of drug discovery projects is the selection of a therapeutic target which is largely driven by its presumed pathogenic involvement. For nervous system diseases, however, the feasibility of identifying potent molecules within the stringent range of molecular
SUBMITTER: Mueller LG
PROVIDER: S-EPMC10988710 | biostudies-literature | 2024 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA